Repertoire Immune Medicines has formed its second pharmaceutical partnership since changing course a few years ago, announcing Wednesday a new deal with Roche’s Genentech division to develop treatments for an unspecified autoimmune disease.

Repertoire Immune Medicines 自几年前改变方向以来，已经达成了第二项制药合作伙伴关系。该公司周三宣布与罗氏旗下基因泰克部门达成新协议，将为一种未指明的自身免疫疾病开发治疗方法。

Genentech will pay Repertorie, a startup launched by biotechnology company creator Flagship Pioneering, $35 million upfront to start the collaboration. Repertoire will then lead early discovery work, with Genentech handling development and eventually commercialization. The startup could receive up to $730 million in future payouts, as well as sales royalties, if the alliance yields any marketed medicines. .

基因泰克将向由生物技术公司创始人旗舰先锋公司创立的初创公司Repertorie支付3500万美元的预付款，以启动合作。Repertoire将主导早期发现工作，基因泰克负责开发并最终实现商业化。如果该联盟推出任何上市药物，这家初创公司未来可能获得高达7.3亿美元的付款以及销售版税。

Repertoire is built around a technology dubbed Decode that’s designed to

Repertoire 围绕一项被称为 Decode 的技术构建，该技术旨在

identify the components of the “immune synapse,”

识别“免疫突触”的组成部分，

a type of junction between white blood cells that plays a key role in immune responses. Repertoire uses that information to uncover drugs for cancer and autoimmune conditions and, so far, has publicly disclosed nine bispecific antibodies or vaccines in its

一种白细胞之间的连接类型，在免疫反应中起关键作用。Repertoire 利用该信息来发现用于癌症和自身免疫疾病的药物，并且到目前为止，已经公开披露了九种双特异性抗体或疫苗在其研究中。

pipeline

管道

. All are in preclinical testing.

所有项目均处于临床前测试阶段。

Repertoire made much of that progress after a strategic reset, however. The company originally launched with a plan to make personalized cell therapies, but pivoted, laid off staff and switched its leadership after early study data disappointed.

然而，Repertoire在战略重置后取得了很大进展。该公司最初计划推出个性化细胞疗法，但在早期研究数据令人失望后，公司进行了转型、裁员并更换了领导层。

That directional change yielded a partnership last year with

这一方向的转变促成了去年的一次合作

Bristol Myers Squibb

百时美施贵宝

to make “

制作“

tolerizing

耐受

” vaccines for autoimmune disorders. And around that time, Repertoire and Roche began engaging in deal talks too, according to CEO

“针对自身免疫性疾病的疫苗。据首席执行官透露，大约在那个时候，Repertoire 和罗氏也开始进行交易谈判。”

Torben Straight Nissen

托本·斯特雷特·尼森

.

。

The two collaborations have helped Repertoire navigate a tumultuous funding climate for drug startups. The company made partnerships a “core” piece of its strategy, in part because alliances could “create a path forward that was independent of, and less reliant on, raising capital through equity.”

这两项合作帮助 Repertoire 应对了药物初创公司动荡的融资环境。该公司将合作伙伴关系作为其战略的“核心”部分，部分原因在于联盟能够“创造一条不依赖于、且较少依赖通过股权融资获取资本的前进道路。”

“It harkens back to how biotech used to be in the old days,” he said, when startups could use pharma deals to “move up the value chain.”

“它让人回想起生物技术在过去的模样，”他说，那时初创公司可以利用制药交易“向价值链上游移动”。

Repertoire will help Roche develop therapies that treat an immune condition by targeting T cells. The companies aren’t divulging more specifics, including the disease at the center of the deal. However, Roche has been particularly active in immunology in recent years, cutting deals to acquire gut disease drug developer .

Repertoire将帮助罗氏开发通过靶向T细胞治疗免疫疾病的方法。两家公司并未透露更多具体信息，包括这项交易核心的疾病。然而，近年来，罗氏在免疫学领域表现得尤为活跃，达成了多项收购肠道疾病药物开发商的协议。

Telavant

特拉万特

as well as autoimmune and cancer cell therapy maker

以及自身免疫和癌症细胞治疗制造商

Poseida Therapeutics

姿势达治疗公司

.

。

Roche has also been studying

罗氏公司也在研究

multiple

多个

bispecific T cell

双特异性T细胞

engagers

参与者

, among them its lymphoma drug Lunsumio, in lupus.

，其中还包括其淋巴瘤药物Lunsumio，在狼疮方面。

“We look forward to translating the new discoveries Decode and the team at Repertoire will reveal to develop novel medicines for patients suffering from autoimmune diseases,” Boris Zaïtra, Roche’s head of corporate business development, said in a statement.

“我们期待着翻译Decode和Repertoire团队将揭示的新发现，以开发针对自身免疫疾病患者的新药物，”罗氏公司企业业务发展主管鲍里斯·扎伊特拉在一份声明中表示。